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OBJECTIVES:More than 7000 rare diseases have been identified, and mostly have a
genetic disorder. In 1983, the Orphan Drug Act was implemented in the United
States to encourage the development of drugs for rare diseases. Since then, many
orphan drugs have been developed but payers concern about their high prices due
to a limited health care budget. In this article we tried to find a solution against lack
of methodologies and evidences for pricing and reimbursement of orphan drugs
and represent the results graphically. METHODS: Cerezyme, Myozyme and Ela-
prase are reimbursed for rare diseases in Korea. We adopted 3 products to estimate
the affordable threshold in cost-effectiveness plane along two properties: 1) reflec-
tion of the cost increase in the health care budget, and 2) index of effectiveness
including the prevalence, severity and efficacy for each product. Then we modeled
a new product by changing its properties and showed results. RESULTS: We de-
fined and analyzed the function of affordable threshold based on cost and index of
effectiveness in two dimensions. The index of effectiveness was calculated from
0.60 to 0.85 and median cost was distributed between 1.8 and 3.0 hundred million
won per year approximately. The affordable threshold for new drug highly depends
on weights of prevalence, severity and efficacy. CONCLUSIONS: Evidences for rare
diseases are often generated from the surrogate outcome, small population and no
comparator. Therefore, it is difficult to assess cost-effectiveness of drugs for rare
diseases with current approach. We showed that the affordable threshold can be
calculated by the products’ properties and monitoring periodically. This method
needs the social agreement for weights and we discuss further limitations.
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THE PAST AS PROLOGUE: USE OF COMPARATIVE EFFECTIVENESS REVIEWS
(CER) IN NATIONAL COVERAGE DECISION MAKING BY MEDICARE IN THE
UNITED STATES AND PREDICTIONS ON FUTURE USE OF CER
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1Avalere Health LLC, Washington, DC, USA, 2Institute for Clinical and Economic Review, Boston,
MA, USA
OBJECTIVES: 1) Review all Medicare national coverage determinations (NCDs) from
2007 through 2011 to identify how CER was explicitly an impetus for or considered
in the decision, and 2) Make inferences on Medicare’s future use of CER from past
behavior and recent health reform developments. METHODS: We reviewed docu-
mentation to identify whether a comparative study or health technology assess-
ment (HTA) was cited in Medicare’s decision initiation rationale or referenced in
the decision. Specifically, we determined the: 1) Number of NCDs and degree to
which CER was used; 2) Types of products and services (e.g., device, procedure); 3)
Therapeutic areas; 4) Organizations producing technical CER materials; 5) Inclusion
of cost effectiveness; and 6) Frequency and content of a coverage with evidence
development (CED) requirement. We characterized Medicare’s historical coverage
and payment behavior and prognosticated on how aspects of health reform may
affect future CER use. RESULTS: More than 55% or 36 NCDs considered CER, with
radiological procedures and diagnostic/screening tests comprising over half.
Sources for the CER technical work were 5 US and 5 international organizations.
Eleven of the decisions considered cost effectiveness; 4 reported a cost-effective-
ness ratio. While a minority, CED judgments increased over time. Medicare has
historically covered and set reimbursement levels that allow for the cost of care
plus some profit, only recently and selectively considering evidence of comparative
clinical or cost effectiveness. While provisions of the Affordable Care Act and reg-
ulatory changes promote the greater use of CER, there are official and practical
impediments that serve as a counterbalance. CONCLUSIONS: Medicare increas-
ingly will use CER in making NCDs but in ways less straightforward than predicted.
While many methods are available to Medicare, perhaps the most promising in the
current political environment are evidence threshold “creep”, CED, and several
novel applications of CER to coverage, coding, and pricing.
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THE ROLE OF MOLECULAR TESTS IN SHAPING COMPARATIVE EFFECTIVENESS
REVIEW (CER)
Hughes KE, Williams R
Avalere Health LLC, Washington, DC, USA
OBJECTIVES: 1) Perform a comprehensive review of the US molecular testing envi-
ronment; 2) Infer from RESULTS:Diagnostic/treatment areas most likely to include
comparative effectiveness reviews (CER) involving molecular testing, how CER will
be shaped by molecular diagnostics, evidence used in coverage decisions; and 3)
Determine global generalizability of US trends. METHODS: We reviewed: 1) All
non-perinatal molecular tests with actual or potential for CER interface, all Medi-
care national (NCDs) and selected local coverage decisions (LCDs) involving molec-
ular tests and CER, and US government and related agency high priority disease
areas for CER, assessing actual or potential molecular testing inclusion, and 2) We
inferred: Clinical areas most likely involving molecular diagnostics and CER,iIm-
pact of molecular testing on CER, evidence required for Medicare/other payer cov-
erage, and universality of US findings. RESULTS: 1) Inventory indicates 442 molec-
ular tests/combinations of interest; 259 have potential degrees of CER interface; 2)
Medicare database yielded: 2 NCDs (Screening DNA Stool Test for Colorectal Can-
cer, Pharmacogenetic Testing for Warfarin Response), 9 LCDs and articles: many
denials of molecular test coverage, denials cite lack of evidence, including trials,
clinical utility, and few cite cost-effectiveness data; 3) Five governmental or health
technology assessment organizations point to 14 clinical areas as highest CER pri-
orities: six known to have associated molecular tests; 5 already involved CER ac-
tivity, and another 7 predicted to have future molecular testing and CER activity per
identified priority areas for research. CONCLUSIONS: Expect molecular testing: to
play an increasing future role in CER, particularly in 7 areas (cancer and hemato-
pathology most prominently, inclusion will necessitate more methodologically so-
phisticated CER, will make cost-effectiveness part of CER, will require strong clin-
ical utility evidence for payer coverage, and trends will be universal and more
pronounced ex-US.
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A COMPARISON OF HTA RECOMMENDATIONS ISSUED BY AGENCY FOR
HEALTH TECHNOLOGY ASSESSMENT IN POLAND (AHTAPOL) AND NATIONAL
INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE (NICE) IN THE UK –
CONSIDERATION OF SOCIAL IMPLICATIONS IN HTA
Cegłowska U, Kolasa K, Hermanowski T
Department of Pharmacoeconomics, Medical University of Warsaw, Warsaw, Poland
OBJECTIVES:Verification whether social implications were considered in HTA pro-
cess in Poland and the UK. METHODS: The comparative analysis included follow-
ing stages: 1) HTA recommendations issued in the period of January 2010 to May
2011 for AHTAPol and September 2010 to May 2011 for NICE; 2) HTA recommenda-
tions were labeled as positive, negative or other (when outcome was neither posi-
tive nor negative); 3) Check-list was composed on the basis of INAHTA definition of
social issues in HTA and also of a definition which additionally introduced changes
in equity and access as a social effect of implementation of a technology. Social
issues were grouped in 6 categories; and 4) The impact of consideration of social
implications in HTA recommendations was determined. RESULTS: Total of 132
AHTAPol Recommendations and 13 NICE Technology Appraisals issued in 2010
were reviewed (in 2 cases, because of the lack of evidence, NICE was unable to make
a recommendation). Social implications were found in respectively: 27% and 82% of
recommendations. The impact of social implications on HTA recommendations
was more common in the UK. In total 59 and 12 were reviewed for AHTAPoL and
NICE, social implications were found in respectively: 46% and 83% of recommen-
dations. The impact of social implications on HTA recommendations was more
common in the UK. Social implications, frequently raised by AHTAPol during the
analyzed period, were: changes in access to health care (48%), influence on pa-
tient’s functioning in society (15%), patient’s ability to work (14%) and others (21%
- mainly, avoidable hospitalization). NICE paid more attention to: changes in access
to health care (26%), influence on patient’s functioning in society (15%), influence
on subcultures (15%) and others (35% - mainly, discrimination). CONCLUSIONS:
During the analyzed period, NICE considered social implications more frequently
than AHTAPol. NICE and AHTAPol paid attention to different types of social impli-
cations.
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TO WHAT EXTENT DOES ADVICE FROM THE SCOTTISH MEDICINES
CONSORTIUM (SMC) AGREE WITH THAT PUBLISHED BY NICE?
Leonard SA1, Brooks-Rooney C2, Kusel J2, Costello S1
1Costello Medical Consulting, Cambridge, UK, 2Costello Medical Consulting Ltd, Cambridge, UK
OBJECTIVES: In the UK, the National Institute for Health and Clinical Excellence
(NICE) assesses the cost-effectiveness of therapies in England and Wales. In Scot-
land, the Scottish Medicines Consortium (SMC) is responsible for such decisions.
There are recognised differences in how these agencies operate, with the SMC
adopting an early, rapid approach to health technology appraisal and NICE favour-
ing a more extensive, detailed review. Conflicting decisions between the two agen-
cies can lead to differential drug availability; however, it is generally believed that
the recommendations are broadly the same. The purpose of this review is to eval-
uate the level of agreement over the last year. METHODS: The NICE website was
searched for single technology appraisals (STAs) published between January and
December 2010. The appraisals for the same drugs were identified on the SMC
website and the recommendations of NICE and the SMC compared. RESULTS:
Nineteen STAs were performed by NICE in 2010. These included 11 drugs for cancer
indications and an assortment of 8 others. Of the 19 drugs evaluated, NICE recom-
mended 12 and rejected 7. For the same drugs, the SMC recommended 8 and
rejected 11. Decisions between the agencies were the same for 13 drugs, equating to
agreement in 68.4% of cases. Of the 6 cases where the recommendation differed, 5
were recommended by NICE. In all five cases the SMC found that the economic
cases presented by the manufacturers were not sufficiently robust: in one instance
weaknesses in the clinical data were also implicated. The one drug recommended
by the SMC in contradiction of NICE was also rejected based on cost-effectiveness.
CONCLUSIONS: In general, there is reasonable agreement between decisions made
by NICE and the SMC. Poor evidence regarding cost-effectiveness is the most com-
monly cited reason for one agency not recommending a drug.
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PERSONALIZED DECISION MAKING IN CANCER MEDICINE? SYSTEMATIC
OVERVIEW OF HTA PROCEDURES AND SPECIFIC APPROACHES IN TEN
COUNTRIES ACROSS FOUR CONTINENTS
Schwarzer R1, Rochau U1, Mühlberger N1, Jahn B1, Sroczynski G1, Schnell-Inderst P1,
Schall I1, Kallinger S1, Lackner M1, Siebert U2
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OBJECTIVES: Capacity constraints jeopardize health care systems’ sustainability
all over the world while the number of Health Technology Assessment (HTA) agen-
cies continues to increase. Explicit or implicit use of cost-effectiveness thresholds
based on HTA/economic evaluations should indicate whether a technology is
worth its costs. Personalized cancer medicine (PCM) promises to be different from
established technologies raising the question whether decision making also differs
for PCM. Our goal was to identify cost-effectiveness thresholds in general or spe-
cific to PCM to finally provide input for decision makers and expert panels.
METHODS: A conceptual evaluation framework was developed comprising eight
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domains including 93 items. We enhanced our previous selection of only European
HTA agencies (IQWiG, DAHTA@DIMDI, NICE, HAS, SBU) by AHRQ, MSAC, LBI, BIQG
/ GOEG, CADTH, DECIT-CGATS, HITAP. Information was collected and compared
quantitatively, choosing the item ‘cost-effectiveness threshold’ as key informa-
tion. Additionally, HTA agencies’ methodological guidelines were extracted for
PCM relevant information. Finally, information was entered into the database and
compared qualitatively. RESULTS: First five agencies differed highly in eight do-
mains (organization scope, processes, methods, dissemination, decision, imple-
mentation, and impact). They agreed in only 17-40%. Enhancement by further
agencies indicates continued heterogeneity. UK (US$32.000-48,000) and Thailand
(US$9,866) indicated explicit but generic (i.e. not specific to disease or type of tech-
nologies) thresholds; implicit use was identified in five countries (Australia, Brazil,
Canada, Sweden, USA). Germany explicitly uses disease-specific cost-effectiveness
ratios. In none of the included countries cost-effectiveness thresholds specific to
personalized medicine and/or oncology were identified, even though we found
exception rules in UK. CONCLUSIONS: Based on a systematic and comprehensive
contextual framework displaying HTA in 10 countries of four continents we iden-
tified large heterogeneity in the application of HTA. Specific guidance for innova-
tive and costly cancer interventions is lacking.
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CLINICAL TRIAL LEARNING CURVES MAY IMPACT BOTH CLINICAL AND
ECONOMIC OUTCOMES, AND INFLUENCE HEALTH TECHNOLOGY ASSESSMENT
AND REIMBURSEMENT DECISION MAKING
Spinner DS1, Mladsi DM1, Walter JW1, Stafford-Smith M2, Taekman JM2, Faulkner EC1
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Duke University Medical Center,
Durham, NC, USA
OBJECTIVES:We previously presented evidence suggesting that clinical trial learn-
ing curves may affect clinical outcomes in patients in drug trials. In the current
analysis, we demonstrate the potential effect of learning curves on economic out-
comes (specifically, cost-effectiveness). METHODS: The PROWESS trial, which
evaluated drotrecogin alpha (DrotAA) for severe sepsis, was identified in our pre-
vious study and was chosen for further analysis based on several considerations: a
published analysis suggested that a clinical trial learning curve may have had a
substantial effect on outcomes in a subgroup of patients (APACHE II  25); and a
published cost-effectiveness analysis (which did not account for the learning curve
effect) was transparent and easily replicable. Furthermore, a health technology
appraisal (HTA) of DrotAA conducted in the UK cited the cost-effectiveness analy-
ses, which suggested that the incremental cost per quality-adjusted life year for
patients with APACHE II scores  25 was  US$400,000. Similarly, an Australian
reimbursement decision excluded this patient subpopulation from coverage citing
unacceptable cost-effectiveness. We replicated the cost-effectiveness analysis for
DrotAA, and used it to model the cost-effectiveness of DrotAA in the subgroup of
patients with APACHE II 25, both with and without the patients enrolled earlier in
the trial and thus potentially affected by the learning curve. RESULTS: When pa-
tients who may have been affected by the trial learning curve were excluded from
the analysis, cost-effectiveness of DrotAA improved significantly, from US$411,333
per LYG with all patients with APACHE II score 25 to US$46,395 per LYG when the
first block of patients enrolled at each site was removed from the analysis.
CONCLUSIONS: Clinical trial learning curves potentially affect both clinical and
economic outcomes, and impact reimbursement decisions. Consideration of learn-
ing curves may be important in HTAs and reimbursement decisions, particularly
when evaluating trial data in which learning curves are more likely to be present.
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OVERVIEW OF HTA PROCESS AND IMPLEMENTATION AMONG HEALTH
STAKEHOLDERS IN BOSNIA AND HERZEGOVINA – SURVEY BASED RESEARCH
Catic T1, Begovic B2
1Society for Pharmacoeconomics and Outcomes Research in Bosnia and Herzegovina, Sarajevo,
Bosnia, 2Clinical Centre University of Sarajevo, Sarajevo, Bosnia
OBJECTIVES: Health Technology Assessment (HTA) is relatively new concept for
Bosnia and Herzegovina health care decision-makers. Decision on reimbursement
of medicines and other technologies are made on different levels due to decen-
tralised health system and by different stakeholders (Entities/Cantonal Health In-
surance Funds-HIF, Hospitals, Ministries of Health-MoH). Objective of this survey
was skreening of current situation and understanding of HTA principles, process
and implementation in decision making proces among key stakeholders.
METHODS: A 9-question survey with INAHTA definition of HTA provided has been
distibuted to 50 stakeholders with potential influence on reimbursement decisions.
Survey include questions on current practices and process of reimbursement de-
cisions, existance of HTA body/commission, criteria for decisions and reasons for
de-listing of reimbursed technologies. Deadline for response was two months.
RESULTS: Overall response rate was 30%; 50% (6/12) of Ministries of Health, 42%
(5/12) Health Inusrance Funds and 17% (4/24) Hospitals respond. 73% respondents
use criteria for decisions on drug reimbursement, and 67% in case of other tech-
nologies. Mostly used criteria are expert opinions (47%) and pharmacoeconomic
studies provided by the manufacturer/presentative (40%), while 33% use referal
pricing as criteria. Most of respondents use mixed criteria. HTA bodies in form of
commission/expert boards are established in 7 institutinons, mostly in MoH and
HIFs. This bodies consist of physitians and pharmacists, and only two of respon-
dents include economicst into these bodies. Similar situation is observed in case od
medical devices and other technologies reimbursement decisions. De-listing is
recorded in 40% respondents but main reason was production discontinuation.
CONCLUSIONS: Although the response rate is low, it allows conclusions that cor-
relate with the experience and current practices. There is a need for a systematic
approach to HTA and adoption of clearer criteria for reimbursement decision-
making. Establishing HTA bodies consisted of trained professionals would improve
the HTA process and reimbursement decisions.
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IMPACT OF PATIENT ACCESS SCHEMES ON NICE AND SMC GUIDANCE
Cooke CL
Complete Medical Group, Macclesfield, Cheshire, UK
OBJECTIVES: To determine whether the use of patient access schemes (PAS) in the
provision of NICE and SMC guidance could be brought into greater alignment,
leading to greater cost savings. METHODS: From a survey of technology appraisals
published on the SMC and NICE websites, the total number involving a PAS has
been assessed. Further, if a PAS is included for a particular drug in one set of
guidance, a comparison has been made of the equivalent guidance by the other
body. There are differences between NICE and SMC roles: NHS England should
fund/resource treatments recommended by NICE; NHS Scotland is expected to
consider SMC advice, but it is not binding. SMC issues guidance on all newly li-
censed medicines, unlike NICE, which prioritizes guidance where it is most needed.
RESULTS: The list of positive NICE appraisals based on the inclusion of a PAS
consists of 15 pharmaceuticals, while the same list for the SMC includes only nine.
Most products with a PAS are included in both sets of guidance, with seven of the
nine SMC PAS also included in the NICE guidance. The remaining two with SMC
PAS have not been assessed by NICE. Of eight NICE PAS not included in SMC guid-
ance, four were accepted/accepted with restricted use, e.g. lenalidomide. The NICE
PAS ensures that if a patient receives 26 treatment cycles, the manufacturer will
cover the cost of further cycles. No PAS is included in SMC guidance; therefore, NHS
Scotland has no cost cap. CONCLUSIONS: PAS are more frequently included in
manufacturers’ submissions to NICE than to SMC. SMC has approved a number of
therapies for which NICE required a PAS to improve the economic argument.
Therefore, for these drugs, NHS Scotland could potentially achieve greater cost
savings if SMC demanded similar PAS to those required by NICE.
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IN DEPTH ANALYSIS OF HEALTH TECHNOLOGY INCORPORATION IN BRAZIL. IS
THERE A COST-EFFECTIVENESS MEASURE OF THRESHOLD?
Santos EAV1, Comparini LB2, Buschinelli CT1
1Roche Brazil, São Paulo, Brazil, 2Bristol-Myers Squibb Brazil, São Paulo, Brazil
OBJECTIVES: Recently, a study conducted in Brazil (Teich et al, 2010) evaluated the
decisions and process submitted to the Brazilian Commission on Health Technol-
ogy Incorporation (CITEC), classifying them according to therapeutic area, re-
sponse type and applicant. The study concluded that there is no clear definition of
priorities for the incorporation of a new technology; however, it did not analyze a
possible cost-effectiveness threshold for decision making. Therefore, the present
study aims to evaluate the existence of economic analysis which supports CITEC
decisions and map possible trends. METHODS: CITEC decisions and technologies
for analysis were obtained from the updated list available at the Ministry of Health
website. Only economic studies (cost-effectiveness/utility, cost-minimization and
budget impact) from the Brazilian perspective were included and the following
databases were consulted: “Medline”, “SciSearch”, “Embase”, “Biosis Preview” and
“ISPOR Outcomes Research Digest”. RESULTS: Technologies were classified in 3
categories: incorporated, not-incorporated and in-analysis; and the results from
economic evaluations were classified into: dominant /cost-saving; up to
$Brz30,000; $Brz30,000-50,000; $Brz50,000-100,000 and above $Brz100,000 per out-
come (ideally QALY or LY, but others were considered). Of the technologies that
were not-incorporated, only 2 presented economic evaluation from Brazilian per-
spective: 1 study with incremental cost up to $Brz30,000 and 1 between $Brz50-
100,000. From incorporated technologies, only 20% presented economic evalua-
tions with results belonging to all categories (including above $Brz100,000 per
outcome). From technologies in analysis, 20% had economic studies, being most of
them dominant or cost-saving.CONCLUSIONS:Apparently, there is no criterion for
health technology assessment and inclusion of new technologies in Brazilian pub-
lic system (SUS) and also a lack of quality in the economic analysis conducted.
Therefore, besides the absence of priorities, the absence of criteria for technology
incorporation could potentially lead the system to be inefficient, spending more
money than necessary and not adopting cost-saving therapies.
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SOCIETAL PREFERENCES FOR HEALTH TECHNOLOGY DISINVESTMENT POLICY:
VIEWS OF SCOTTISH TAXPAYERS – A QUALITATIVE STUDY
Hislop JM
University of Aberdeen, Aberdeen, UK
OBJECTIVES: Increasingly challenging economic times require challenging deci-
sions to be made regarding health technology disinvestment. Insufficient evidence
exists on societal preferences for disinvestment in publicly-funded health care
systems. This research sought to explore the acceptability of disinvestment to
Scottish taxpayers, their preferences, and whether taxpayer loss aversion is a rel-
evant factor for disinvestment policy development. METHODS: Qualitative inter-
views were conducted with a sample of Scottish taxpayers. Interviews were split
into four parts to progress thematic discussion from basic to complex, examine
consistency and identify responses potentially indicative of loss aversion. Partici-
pants were asked about their general views on the NHS and disinvestment (Part 1),
scenario-based questions on disinvestment (Part 2), to freely discuss the disinvest-
ment issues they considered important and who they thought should be involved
in making decisions (Part 3), and further scenario-based questions on health tech-
nology investment (Part 4). RESULTS: Twelve interviews were undertaken. Re-
sponses were generally consistent. Scottish taxpayers notionally accepted disin-
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